Immunicum AB Aktie
WKN DE: A1W59F / ISIN: SE0005003654
|
14.05.2018 12:00:16
|
Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in May and June
Press Release
14 May 2018
Immunicum AB (publ) Announces Upcoming Presentations and Attendances at Conferences in May and June
Immunicum AB (publ; IMMU.ST) today announced that Company leadership will present the corporate overview, participate on an immuno-oncology panel and attend upcoming industry conferences in May and June.
Bio€quity Europe
Date: May 14 - 16, 2018
Presentation: Wednesday, May 16, 10:20 - 10:40 am Central European Summer Time
Venue: Universiteit Gent - Het Pand, Ghent, Belgium
RedEye Investor After Work Stockholm
Date: May 22, 2018
Presentation: 6:00 - 6:20 pm Central European Summer Time
Venue: Mäster Samuelsgatan 42, 111 57 Stockholm, Sweden
Please register to attend at: http://bit.ly/2HUwBGm
Sachs Associates 4th Annual Immuno-Oncology: BD&L and Investment Forum
Date: June 1, 2018
Panel: Latest Developments in IO & Combination Therapies - 10:40 am Central Daylight Time
Presentation: 12:20 - 12:40 pm Central Daylight Time
Venue: Waldorf Astoria Chicago Hotel, Chicago, Illinois, USA
BIO International Convention
Date: June 4 - 7, 2018
Venue: Boston Convention & Exhibition Center, Boston, Massachusetts, USA
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ)Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm www.immunicum.com |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Immunicum ABmehr Nachrichten
| Keine Nachrichten verfügbar. |
Analysen zu Immunicum ABmehr Analysen
Aktien in diesem Artikel
| Immunicum AB | 0,51 | 6,07% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.